Saturday 17 October 2026
Export PMCB’s income statement to Excel — free account
Nuvilex Inc.
PMCB Healthcare Biotechnology
In the quarter to July 2026, EPS grew 56.1% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.34
0.02
−5.56%
Follow PMCB
Nuvilex Inc. (PMCB) P/E ratio
Nuvilex Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.5× (November 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 3.5×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IOBTQ IO Biotech, Inc. compare | n/m |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | n/m |
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| KALA KALA BIO, Inc. compare | n/m |
| PMCB Nuvilex Inc. | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)